JosÃ© Baselga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7832584/publications.pdf

Version: 2024-02-01

160 papers	46,733 citations	78 h-index	158 g-index
		7096	6300
162 all docs	162 docs citations	162 times ranked	47876 citing authors

#	Article	IF	Citations
1	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 2001, 344, 783-792.	27.0	10,216
2	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
3	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	27.0	2,474
4	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
5	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	27.8	1,391
6	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
7	The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19, 6550-6565.	5.9	1,251
8	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2012, 379, 633-640.	13.7	1,165
9	Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 2012, 486, 405-409.	27.8	1,107
10	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9, 463-475.	28.4	993
11	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 2013, 45, 1439-1445.	21.4	960
12	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
13	Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. Journal of Clinical Oncology, 2005, 23, 2445-2459.	1.6	676
14	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
15	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. Journal of Clinical Oncology, 2010, 28, 1138-1144.	1.6	593
16	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637.	1.6	582
17	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
18	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572

#	Article	IF	Citations
19	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptorâ€“Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.9	509
20	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
21	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244.	27.8	486
22	Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2005, 23, 5568-5577.	1.6	473
23	Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 2006, 312, 1175-1178.	12.6	437
24	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 904-916.	10.7	427
25	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	21.4	411
26	Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599.	28.9	405
27	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	1.6	381
28	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
29	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
30	Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 5323-5333.	1.6	334
31	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
32	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunology, 2020, 5, .	11.9	304
33	Phosphatidylinositol 3-Kinase Î±â€“Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology, 2018, 36, 1291-1299.	1.6	298
34	Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive, First-Line Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3753-3761.	1.6	296
35	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	27.8	295
36	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery, 2017, 7, 277-287.	9.4	286

#	Article	IF	Citations
37	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	12.4	276
38	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	9.4	275
39	Recurrent and functional regulatory mutations in breast cancer. Nature, 2017, 547, 55-60.	27.8	269
40	AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	16.8	263
41	BRAF Inhibition in BRAF^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	1.6	247
42	AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	1.6	240
43	Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. , 1997, 80, 1966-1972.		221
44	Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. Oncologist, 2011, 16, 12-19.	3.7	221
45	PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science, 2017, 355, 1324-1330.	12.6	217
46	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381.	6.4	215
47	Feedback Suppression of PI3KÎ± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3KÎ². Cancer Cell, 2015, 27, 109-122.	16.8	203
48	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology, 2016, 34, 419-426.	1.6	203
49	First-in-Human Dose Study of the Novel Transforming Growth Factor-Î² Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research, 2015, 21, 553-560.	7.0	199
50	Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer. Oncologist, 2006, 11, 4-12.	3.7	198
51	p95HER2 and Breast Cancer. Cancer Research, 2011, 71, 1515-1519.	0.9	195
52	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition. Cancer Cell, 2016, 30, 229-242.	16.8	187
53	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptorâ€“Positive Advanced Breast Cancer. JAMA Oncology, 2019, 5, e184475.	7.1	187
54	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	12.6	185

#	Article	IF	Citations
55	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	178
56	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	6.9	169
57	P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science Translational Medicine, 2016, 8, 345ra87.	12.4	152
58	Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1484-1491.	1.6	151
59	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 2009, 29, 3319-3331.	2.3	150
60	Somatic PIK3CA mutations as a driver of sporadic venous malformations. Science Translational Medicine, 2016, 8, 332ra42.	12.4	147
61	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113.	27.8	142
62	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics, 2020, 52, 198-207.	21.4	140
63	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	7.1	139
64	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	6.4	136
65	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discovery, 2017, 7, 102-113.	9.4	136
66	CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 489-491.	2.4	128
67	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3626-3633.	1.6	118
68	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	7.1	118
69	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology, 2018, 36, LBA1006-LBA1006.	1.6	116
70	Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
71	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2â^' advanced breast cancer: results from BOLERO-2. British Journal of Cancer, 2017, 116, 726-730.	6.4	112
72	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discovery, 2016, 6, 1134-1147.	9.4	106

#	Article	IF	Citations
73	Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. Journal of Clinical Oncology, 2009, 27, 526-534.	1.6	102
74	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
75	Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research, 2010, 16, 4876-4883.	7.0	99
76	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
77	Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clinical Cancer Research, 2016, 22, 1313-1317.	7.0	92
78	Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 14292.	12.8	90
79	Focus on breast cancer. Cancer Cell, 2002, 1, 319-322.	16.8	84
80	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	9.4	83
81	The hVps34â€•<scp>SGK</scp> 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating <scp>mTORC</scp> 1 and tumourÂgrowth. EMBO Journal, 2016, 35, 1902-1922.	7.8	77
82	Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. Cancer Research, 2013, 73, 450-458.	0.9	76
83	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 1226-1238.	10.7	76
84	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	7.0	71
85	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing ActivatingPIK3CAAlterations. Clinical Cancer Research, 2016, 22, 2009-2019.	7.0	70
86	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	16.8	67
87	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	7.0	66
88	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64
89	TGF-Î² signalling-related markers in cancer patients with bone metastasis. Biomarkers, 2008, 13, 217-236.	1.9	60
90	p95HER2â€“T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	12.4	59

#	Article	IF	Citations
91	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
92	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	7.0	54
93	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
94	Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3030-3035.	7.1	52
95	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology, 2018, 36, 3126-3133.	1.6	52
96	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European Journal of Cancer, 2018, 103, 147-154.	2.8	52
97	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clinical Cancer Research, 2015, 21, 2462-2470.	7.0	51
98	Survival outcomes of the NeoALTTO study (BIG 1â€“06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European Journal of Cancer, 2019, 118, 169-177.	2.8	51
99	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research, 2015, 21, 49-59.	7.0	49
100	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
101	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptorâ€“Positive Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 4380-4387.	7.0	49
102	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell Reports, 2019, 27, 294-306.e5.	6.4	49
103	A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell, 2002, 2, 93-95.	16.8	48
104	A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. Cancer Research, 2010, 70, 8537-8546.	0.9	47
105	Stratification and therapeutic potential of PML in metastatic breast cancer. Nature Communications, 2016, 7, 12595.	12.8	45
106	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation. Cancer Discovery, 2013, 3, 1238-1244.	9.4	43
107	Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology, 2017, 119, 113-122.	4.4	42
108	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	4.6	37

#	Article	IF	Citations
109	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	6.3	36
110	Therapeutic Benefit of Selective Inhibition of p110Î± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	7.0	35
111	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. Oncogene, 1998, 17, 761-767.	5.9	31
112	A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases. Clinical Cancer Research, 2014, 20, 2793-2804.	7.0	31
113	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	5.0	28
114	Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy. Oncologist, 2002, 7, 2-8.	3.7	28
115	Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.. Cancer Research, 2013, 73, LB-64-LB-64.	0.9	26
116	Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. Oncologist, 2001, 6, 26-29.	3.7	25
117	Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy. Cancer, 1993, 71, 2332-2334.	4.1	21
118	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	3.0	20
119	Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. Clinical Cancer Research, 2016, 22, 2099-2101.	7.0	19
120	Next-Generation Sequencingâ€“Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	2.8	19
121	The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. ELife, 2016, 5, e12034.	6.0	19
122	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted byTP53Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	7.0	18
123	A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, 508-508.	1.6	18
124	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. Methods, 2015, 77-78, 25-30.	3.8	16
125	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	1.4	16
126	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research, 2012, 18, 6364-6372.	7.0	14

#	Article	IF	Citations
127	Epidermal growth factor receptor pathway inhibitors. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 205-223.	0.5	14
128	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology, 2018, 4, e181564.	7.1	13
129	Cell Lineâ€“Specific Network Models of ER+ Breast Cancer Identify Potential PI3KÎ± Inhibitor Resistance Mechanisms and Drug Combinations. Cancer Research, 2021, 81, 4603-4617.	0.9	13
130	Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ÃŸ) receptor I kinase inhibitor, LY2157299 monohydrate (LY).. Journal of Clinical Oncology, 2013, 31, 2016-2016.	1.6	12
131	A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1991, 28, 51-54.	2.3	11
132	Abstract PD5-5: Phase I study of the PI3KÎ± inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer. Cancer Research, 2015, 75, PD5-5-PD5-5.	0.9	11
133	Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?. Nature Clinical Practice Oncology, 2005, 2, 284-285.	4.3	10
134	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	5.5	10
135	Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. Cancer Investigation, 1998, 16, 67-71.	1.3	9
136	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. Journal of Clinical Oncology, 2012, 30, 2568-2568.	1.6	9
137	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer, 2021, 7, 145.	5.2	9
138	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of Geriatric Oncology, 2013, 4, 346-352.	1.0	7
139	Case 16-2012. New England Journal of Medicine, 2012, 366, 2018-2026.	27.0	6
140	Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 1009-1009.	1.6	6
141	Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer, 2020, 20, 174-181.e3.	2.4	5
142	SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2012, 30, 1011-1011.	1.6	5
143	The oral transforming growth factor-beta (TGF-ÃŸ) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. Journal of Clinical Oncology, 2012, 30, 2042-2042.	1.6	5
144	Phase Ib combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2012, 30, TPS3118-TPS3118.	1.6	5

#	Article	IF	Citations
145	SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.. Journal of Clinical Oncology, 2016, 34, TPS617-TPS617.	1.6	5
146	Creating a stronger front against cancer: ESMO and ECCO join forces. Annals of Oncology, 2008, 19, 1367-1368.	1.2	4
147	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer, 2021, 125, 38-47.	6.4	4
148	Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors. Cancer Research, 2018, 78, CT046-CT046.	0.9	4
149	BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology, 2012, 30, 125-125.	1.6	4
150	Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 558-558.	1.6	4
151	Abstract CT330: Phase I study of PI3KÎ± inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Cancer Research, 2015, 75, CT330-CT330.	0.9	3
152	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	1.4	3
153	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology, 2012, 30, 102-102.	1.6	2
154	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 99-99.	1.6	2
155	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 553-553.	1.6	2
156	Reply to S.M. Ali et al. Journal of Clinical Oncology, 2009, 27, e274-e275.	1.6	1
157	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	2.4	1
158	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567.	1.6	1
159	Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. Oncologist, 2001, 6, 26-29.	3.7	1
160	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0